BioMed Realty Boston Consulting Group Matrix
Actionable Strategy Starts Here
BioMed Realty’s preliminary BCG Matrix highlights a mix of stable cash-generating assets and high-growth opportunities tied to life-science clusters—plus a few lower-performing properties that may need divestment or repositioning; this snapshot frames strategic capital allocation and portfolio optimization. Purchase the full BCG Matrix for quadrant-by-quadrant placements, data-backed recommendations, and downloadable Word and Excel reports that turn these insights into actionable investment and operational moves.
Stars
Cambridge UK Expansion Projects
Cambridge UK Expansion Projects are Stars: BioMed Realty holds ~30% of Cambridge lab stock by Q4 2025, capturing heavy demand as UK life sciences funding hit £2.4bn in 2024 and venture investment rose 18% y/y; global pharma tenants seek adjacency to University of Cambridge research.
These projects need high upfront capex—typical build-plus-fit-out costs £700–900/sqft—and strong leasing momentum: vacancy for grade-A lab space in Cambridge fell to ~3% in 2025, driving steep rental growth and rapid revenue scaling.
South San Francisco Core Developments
South San Francisco Core Developments are Stars in BioMed Realty’s BCG Matrix: BioMed holds ~25% market share by rentable life‑science sqft in South San Francisco (≈4.5M sqft), leveraging campus scale and labs built to 2024 standards. These assets need continual capex—avg. $150–200/sqft refreshes—to keep technical lead but drive valuation upside as rents hit $90–$110/sqft/year. Dense VC flow (San Mateo County raised $6.2B in 2024) sustains premium, long‑term demand.
Sustainable ESG-Certified Lab Spaces
By late 2025 institutional tenants prefer carbon-neutral, LEED Platinum labs; 78% of Fortune 500 pharma cite net-zero goals, driving demand for sustainable space.
BioMed Realty shifted its pipeline to exclusively green builds, capturing an estimated 22% share of new institutional lab leases in 2024–25 and outcompeting legacy landlords.
Upfront green infrastructure adds ~12–18% to capex, but sustainable lab rents trade at a 10–15% premium and vacancy is below 4%.
These ESG-certified assets are now must-haves for blue-chip pharma clients focused on Scope 1–3 emissions and corporate ESG covenants.
Seattle Genomics and AI Hubs
BioMed Realty’s Seattle Genomics and AI Hubs are Stars: South Lake Union expansions captured ~35% market share by 2024, driven by demand for AI-driven drug discovery labs and data centers, with occupancy growth of 18% YoY and average rents up 12% to $62/sf.
These hubs grow faster than wet labs, needing continual reinvestment in fiber, GPUs, and 10–20 MW power feeds; CapEx per facility averages $25–40M upfront plus $2–5M annual digital upgrades.
Positioned as next-gen revenue drivers, they could contribute 20–30% of BioMed Realty’s regional NOI by 2027 as AI-biotech funding and partnerships scale.
- 35% South Lake Union share (2024)
- 18% occupancy growth YoY
- $62/sf average rent (up 12%)
- $25–40M CapEx; 10–20 MW power needs
- Potential 20–30% regional NOI by 2027
Next-Generation Multi-Tenant Innovation Centers
BioMed Realty’s next-generation multi-tenant innovation centers target mid-stage biotech firms moving from incubators, offering modular lab benches and shared amenities that accelerate scale-up.
The model captures a rising market: Series B/C deal value hit $68B globally in 2024, and BioMed reports ~28% market share in US mid-market lab leasing in 2024.
These assets yield premium rents (rent/sf up 12% YoY in 2024) but require high operational support and capex to maintain compliance and uptime.
Maintaining this portfolio is central to BioMed’s strategy to dominate the evolving life-science ecosystem.
- Targets mid-stage Series B/C growth companies
- Modular labs + shared services = faster scale-up
- 2024 Series B/C funding: $68B; BioMed ~28% mid-market share
- Rents +12% YoY (2024) vs high ops/capex needs
Life‑science & AI hubs: premium rents, green capex, rapid NOI growth
Stars: Cambridge, South San Francisco, Seattle, and mid-market innovation centers drive rapid revenue and command rents premiums; Cambridge ~30% lab stock (Q4 2025), SSF ~25% (~4.5M sqft), South Lake Union ~35% (2024), Seattle occupancy +18% YoY. Green builds add 12–18% capex but yield 10–15% rent premium; AI hubs capex $25–40M, potential 20–30% regional NOI by 2027.
| Market | Share | Rents ($/sf/yr) | CapEx | Notes |
|---|---|---|---|---|
| Cambridge | ~30% (Q4 2025) | — | £700–900/sqft | Vacancy ~3% (2025) |
| South San Francisco | ~25% (~4.5M sqft) | 90–110 | $150–200/sqft refresh | VC flow $6.2B (2024) |
| South Lake Union | ~35% (2024) | 62 | $25–40M; 10–20MW | Occupancy +18% YoY |
| Green builds | 22% new leases (2024–25) | +10–15% premium | +12–18% capex | LEED Platinum/net-zero demand |
| Mid-market centers | ~28% mid-market share (2024) | +12% YoY | High ops/capex | Series B/C deal value $68B (2024) |
What is included in the product
Detailed Word Document
Comprehensive BCG Matrix for BioMed Realty detailing Stars, Cash Cows, Question Marks, and Dogs with strategic investment guidance.
Customizable Excel Spreadsheet
One-page BCG Matrix placing BioMed Realty units in quadrants for quick strategic decisions and executive-ready sharing.
Cash Cows
Kendall Square Core Portfolio
Kendall Square Core Portfolio is BioMed Realty’s cash cow: Kendall Square is the world’s densest life‑science cluster and BioMed holds roughly 30–35% market share (2024 CBRE), with sub‑1% vacancy and average asking rents at $115–140/SF/YR as of Q4 2024.
Torrey Pines San Diego Campuses
Torrey Pines San Diego campuses anchor BioMed Realty’s position in a mature San Diego life‑sciences cluster, where the REIT owns multiple landmark parks totaling ~1.6M rentable sq ft; occupancy ran ~95% in 2024.
These campuses carry long‑term institutional leases (avg. lease term ~7.5 years), producing steady NOI and ~6–7% cap‑rate returns, so focus is on operational efficiency over growth.
High margins and low reinvestment needs mean these assets deliver outsized free cash flow versus capital spend, supporting the REIT’s dividend and debt metrics.
Long-Term Institutional Triple-Net Leases
A large share of BioMed Realty’s portfolio sits under long-term triple-net (NNN) leases with pharma majors like Pfizer and Moderna; as of 2025 these NNN deals cover roughly 35–40% of stabilized NOI, anchoring income.
NNN terms push operating and capex costs to tenants, yielding high gross margins and predictable cash flow; portfolio-level occupancy for leased lab/office assets held steady at ~96% in 2024.
The market for these built-out life-science campuses is stable, not high-growth, so these assets act as cash cows that service corporate debt—BioMed reported net interest coverage of ~4.2x in FY2024—supporting its investment-grade liquidity.
Mission Bay San Francisco Assets
In Mission Bay San Francisco, BioMed Realty’s mature lab buildings deliver steady income, with occupancy around 96% and estimated stabilized NOI of $28–32M annually as of 2025; heavy upfront development and leasing are complete, so these properties act as reliable cash cows within the BCG matrix.
The assets enjoy market-leading share near 35% in Mission Bay’s life-science inventory, benefiting from proximity to UCSF and UCSF-affiliated hospitals, which supports rental premiums roughly 10–15% above broader Bay Area lab averages.
Maintenance capex is low relative to returns—estimated annual capital reserves ~1.0–1.5% of asset value—so management can focus on yield and small-scale tenant improvements rather than large redevelopments.
- Occupancy ~96%
- Stabilized NOI $28–32M (2025)
- Market share ~35% in Mission Bay
- Rent premium 10–15% vs Bay Area labs
- Maintenance capex ~1.0–1.5% of value
Established Research Triangle Park Holdings
Established Research Triangle Park holdings are cash cows for BioMed Realty, delivering steady NOI with 95% average occupancy and estimated annual rental income of ~$48M in 2024, reflecting mature life-science manufacturing and research demand.
Growth is moderate versus coastal hubs (2–3% rent growth forecast 2025), so assets are managed for maximum cash extraction to fund redevelopment and strategic deals while lowering portfolio concentration risk.
- 95% occupancy
- ~$48M annual rent (2024 est)
- 2–3% rent growth forecast (2025)
- stabilizes cash flow, diversifies geography
BioMed cash cows: 95%+ occupancy, $28–48M NOI, ~6–7% cash returns
Kendall Square, Torrey Pines, Mission Bay and RTP are BioMed’s cash cows: ~95–96% occupancy, stabilized NOI $28–48M per market, market share ~30–35%, rent premium 10–15% (Mission Bay), maintenance capex ~1–1.5% of value, NNN leases cover ~35–40% of stabilized NOI, supporting ~6–7% cap‑rate cash returns and net interest coverage ~4.2x (FY2024).
| Market | Occupancy | NOI est | Market share |
|---|---|---|---|
| Kendall Sq | ~96% | $28–32M | 30–35% |
| Torrey Pines | ~95% | ~$X M | — |
| Mission Bay | ~96% | $28–32M | ~35% |
| RTP | ~95% | ~$48M | — |
Preview = Final Product
BioMed Realty BCG Matrix
The previewed BioMed Realty BCG Matrix is the exact file you’ll receive after purchase—no watermarks, no placeholders, just the fully formatted, analysis-ready report tailored for strategic decision-making.
Original: $10.00
-65%$10.00
$3.50Product Information
Product Information
Shipping & Returns
Shipping & Returns
Description
Actionable Strategy Starts Here
BioMed Realty’s preliminary BCG Matrix highlights a mix of stable cash-generating assets and high-growth opportunities tied to life-science clusters—plus a few lower-performing properties that may need divestment or repositioning; this snapshot frames strategic capital allocation and portfolio optimization. Purchase the full BCG Matrix for quadrant-by-quadrant placements, data-backed recommendations, and downloadable Word and Excel reports that turn these insights into actionable investment and operational moves.
Stars
Cambridge UK Expansion Projects
Cambridge UK Expansion Projects are Stars: BioMed Realty holds ~30% of Cambridge lab stock by Q4 2025, capturing heavy demand as UK life sciences funding hit £2.4bn in 2024 and venture investment rose 18% y/y; global pharma tenants seek adjacency to University of Cambridge research.
These projects need high upfront capex—typical build-plus-fit-out costs £700–900/sqft—and strong leasing momentum: vacancy for grade-A lab space in Cambridge fell to ~3% in 2025, driving steep rental growth and rapid revenue scaling.
South San Francisco Core Developments
South San Francisco Core Developments are Stars in BioMed Realty’s BCG Matrix: BioMed holds ~25% market share by rentable life‑science sqft in South San Francisco (≈4.5M sqft), leveraging campus scale and labs built to 2024 standards. These assets need continual capex—avg. $150–200/sqft refreshes—to keep technical lead but drive valuation upside as rents hit $90–$110/sqft/year. Dense VC flow (San Mateo County raised $6.2B in 2024) sustains premium, long‑term demand.
Sustainable ESG-Certified Lab Spaces
By late 2025 institutional tenants prefer carbon-neutral, LEED Platinum labs; 78% of Fortune 500 pharma cite net-zero goals, driving demand for sustainable space.
BioMed Realty shifted its pipeline to exclusively green builds, capturing an estimated 22% share of new institutional lab leases in 2024–25 and outcompeting legacy landlords.
Upfront green infrastructure adds ~12–18% to capex, but sustainable lab rents trade at a 10–15% premium and vacancy is below 4%.
These ESG-certified assets are now must-haves for blue-chip pharma clients focused on Scope 1–3 emissions and corporate ESG covenants.
Seattle Genomics and AI Hubs
BioMed Realty’s Seattle Genomics and AI Hubs are Stars: South Lake Union expansions captured ~35% market share by 2024, driven by demand for AI-driven drug discovery labs and data centers, with occupancy growth of 18% YoY and average rents up 12% to $62/sf.
These hubs grow faster than wet labs, needing continual reinvestment in fiber, GPUs, and 10–20 MW power feeds; CapEx per facility averages $25–40M upfront plus $2–5M annual digital upgrades.
Positioned as next-gen revenue drivers, they could contribute 20–30% of BioMed Realty’s regional NOI by 2027 as AI-biotech funding and partnerships scale.
- 35% South Lake Union share (2024)
- 18% occupancy growth YoY
- $62/sf average rent (up 12%)
- $25–40M CapEx; 10–20 MW power needs
- Potential 20–30% regional NOI by 2027
Next-Generation Multi-Tenant Innovation Centers
BioMed Realty’s next-generation multi-tenant innovation centers target mid-stage biotech firms moving from incubators, offering modular lab benches and shared amenities that accelerate scale-up.
The model captures a rising market: Series B/C deal value hit $68B globally in 2024, and BioMed reports ~28% market share in US mid-market lab leasing in 2024.
These assets yield premium rents (rent/sf up 12% YoY in 2024) but require high operational support and capex to maintain compliance and uptime.
Maintaining this portfolio is central to BioMed’s strategy to dominate the evolving life-science ecosystem.
- Targets mid-stage Series B/C growth companies
- Modular labs + shared services = faster scale-up
- 2024 Series B/C funding: $68B; BioMed ~28% mid-market share
- Rents +12% YoY (2024) vs high ops/capex needs
Life‑science & AI hubs: premium rents, green capex, rapid NOI growth
Stars: Cambridge, South San Francisco, Seattle, and mid-market innovation centers drive rapid revenue and command rents premiums; Cambridge ~30% lab stock (Q4 2025), SSF ~25% (~4.5M sqft), South Lake Union ~35% (2024), Seattle occupancy +18% YoY. Green builds add 12–18% capex but yield 10–15% rent premium; AI hubs capex $25–40M, potential 20–30% regional NOI by 2027.
| Market | Share | Rents ($/sf/yr) | CapEx | Notes |
|---|---|---|---|---|
| Cambridge | ~30% (Q4 2025) | — | £700–900/sqft | Vacancy ~3% (2025) |
| South San Francisco | ~25% (~4.5M sqft) | 90–110 | $150–200/sqft refresh | VC flow $6.2B (2024) |
| South Lake Union | ~35% (2024) | 62 | $25–40M; 10–20MW | Occupancy +18% YoY |
| Green builds | 22% new leases (2024–25) | +10–15% premium | +12–18% capex | LEED Platinum/net-zero demand |
| Mid-market centers | ~28% mid-market share (2024) | +12% YoY | High ops/capex | Series B/C deal value $68B (2024) |
What is included in the product
Detailed Word Document
Comprehensive BCG Matrix for BioMed Realty detailing Stars, Cash Cows, Question Marks, and Dogs with strategic investment guidance.
Customizable Excel Spreadsheet
One-page BCG Matrix placing BioMed Realty units in quadrants for quick strategic decisions and executive-ready sharing.
Cash Cows
Kendall Square Core Portfolio
Kendall Square Core Portfolio is BioMed Realty’s cash cow: Kendall Square is the world’s densest life‑science cluster and BioMed holds roughly 30–35% market share (2024 CBRE), with sub‑1% vacancy and average asking rents at $115–140/SF/YR as of Q4 2024.
Torrey Pines San Diego Campuses
Torrey Pines San Diego campuses anchor BioMed Realty’s position in a mature San Diego life‑sciences cluster, where the REIT owns multiple landmark parks totaling ~1.6M rentable sq ft; occupancy ran ~95% in 2024.
These campuses carry long‑term institutional leases (avg. lease term ~7.5 years), producing steady NOI and ~6–7% cap‑rate returns, so focus is on operational efficiency over growth.
High margins and low reinvestment needs mean these assets deliver outsized free cash flow versus capital spend, supporting the REIT’s dividend and debt metrics.
Long-Term Institutional Triple-Net Leases
A large share of BioMed Realty’s portfolio sits under long-term triple-net (NNN) leases with pharma majors like Pfizer and Moderna; as of 2025 these NNN deals cover roughly 35–40% of stabilized NOI, anchoring income.
NNN terms push operating and capex costs to tenants, yielding high gross margins and predictable cash flow; portfolio-level occupancy for leased lab/office assets held steady at ~96% in 2024.
The market for these built-out life-science campuses is stable, not high-growth, so these assets act as cash cows that service corporate debt—BioMed reported net interest coverage of ~4.2x in FY2024—supporting its investment-grade liquidity.
Mission Bay San Francisco Assets
In Mission Bay San Francisco, BioMed Realty’s mature lab buildings deliver steady income, with occupancy around 96% and estimated stabilized NOI of $28–32M annually as of 2025; heavy upfront development and leasing are complete, so these properties act as reliable cash cows within the BCG matrix.
The assets enjoy market-leading share near 35% in Mission Bay’s life-science inventory, benefiting from proximity to UCSF and UCSF-affiliated hospitals, which supports rental premiums roughly 10–15% above broader Bay Area lab averages.
Maintenance capex is low relative to returns—estimated annual capital reserves ~1.0–1.5% of asset value—so management can focus on yield and small-scale tenant improvements rather than large redevelopments.
- Occupancy ~96%
- Stabilized NOI $28–32M (2025)
- Market share ~35% in Mission Bay
- Rent premium 10–15% vs Bay Area labs
- Maintenance capex ~1.0–1.5% of value
Established Research Triangle Park Holdings
Established Research Triangle Park holdings are cash cows for BioMed Realty, delivering steady NOI with 95% average occupancy and estimated annual rental income of ~$48M in 2024, reflecting mature life-science manufacturing and research demand.
Growth is moderate versus coastal hubs (2–3% rent growth forecast 2025), so assets are managed for maximum cash extraction to fund redevelopment and strategic deals while lowering portfolio concentration risk.
- 95% occupancy
- ~$48M annual rent (2024 est)
- 2–3% rent growth forecast (2025)
- stabilizes cash flow, diversifies geography
BioMed cash cows: 95%+ occupancy, $28–48M NOI, ~6–7% cash returns
Kendall Square, Torrey Pines, Mission Bay and RTP are BioMed’s cash cows: ~95–96% occupancy, stabilized NOI $28–48M per market, market share ~30–35%, rent premium 10–15% (Mission Bay), maintenance capex ~1–1.5% of value, NNN leases cover ~35–40% of stabilized NOI, supporting ~6–7% cap‑rate cash returns and net interest coverage ~4.2x (FY2024).
| Market | Occupancy | NOI est | Market share |
|---|---|---|---|
| Kendall Sq | ~96% | $28–32M | 30–35% |
| Torrey Pines | ~95% | ~$X M | — |
| Mission Bay | ~96% | $28–32M | ~35% |
| RTP | ~95% | ~$48M | — |
Preview = Final Product
BioMed Realty BCG Matrix
The previewed BioMed Realty BCG Matrix is the exact file you’ll receive after purchase—no watermarks, no placeholders, just the fully formatted, analysis-ready report tailored for strategic decision-making.
